6201 gausroid presentation gitanjali avhad & umesh soni
DESCRIPTION
This is an NDA submission presentation in class setting showing a drug submission to treat hypothyroidism.TRANSCRIPT
![Page 1: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/1.jpg)
1
Gaus Pharma
Course: RGA 6201
Instructor: Dr. Anupama Gaur
![Page 2: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/2.jpg)
Gaus Pharma Overview
Hypothyroidism
Market Scenario
Gausroid
Regulatory plan
Post approval strategy
2
![Page 3: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/3.jpg)
“Gaus” means “Foolish Person”.
US based Pharmaceutical Company
Located in Boston
700 Employees
40 Veteran Regulatory Employees.
Filing NDA for Gausroid
3
![Page 4: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/4.jpg)
Deficiency of Thyroid
Hormone.
Acquired or Congenital.
2-5% World Population
3.7% in U.S Population
(~Ten million).
Women > Men
More risk in Elders.
4
![Page 5: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/5.jpg)
Levothyroxine Sodium e.g.
*Synthroid(Abbott)-$520 million
*Levoxyl (Pfizer)- $15.4 million
Problems:
-Effect on bone density
-Unstable
-Potency problem
-Costly
5
![Page 6: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/6.jpg)
Levothyroxine Calcium.
Oral Replacement Therapy
New Improved Formulation:
-Restores Bone Mineral Density
-Lesser Adverse Event
-More Stable
-More Potent
-Economical
6
![Page 7: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/7.jpg)
7
IND Application Filed in eCTD
NDA Application Filed in eCTD
Label Expansion Strategies
GAUSROID
DEVELOPMENT
![Page 8: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/8.jpg)
8
Pharmacology
Toxicology
Single-dose toxicity
Repeat –dose toxicity
Genotoxicity
Carcinogenicity
Immunotoxicity
Reproductive and developmental toxicity
• Primary Pharmacodynamics
• Secondary Pharmacodynamics
• Safety Pharmacology
Pharmacodynamics
•Absorption,
•Distribution,
•Metabolism
• Excretion
Pharmacokinetics
*CFR Title 21 part 58 (GLP)
*ICH Guidelines: Safety, Quality, MultidisciplinaryNon
Clinical studies
![Page 9: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/9.jpg)
9
Gausroid CMC Complies with:
CFR Title 21 part 211 (cGMP)
ICH Guidelines
CMC Contains:
Drug Substance and Drug Product, ICH Q6A
Stability, ICH Q1A (R2)
Manufacturing Process Development
Quality, Identity and Purity ICH Q6A
![Page 10: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/10.jpg)
10
Pre IND:
-Type B Meeting as per 21 CFR 312.82.
Purpose:
To Discuss Scope and Design of Phase I.
To Investigate Shortcomings.
eCTD Format through FDA’s Electronic
Submission Gateway.
![Page 11: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/11.jpg)
11
Clinical Trials After IND Approval
Three phases Studies
Multi Centers Clinical Trials in US
Randomized, Double-Blinded,
Placebo Concurrent trials.
Conducted on Adults
Age 21 yrs-75 yrs.
ICH E6 guidelines: GCP
![Page 12: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/12.jpg)
12
Clinical Studies
Conducted on 50 Healthy Volunteers
Purpose: To Ensure Safety
*To Evaluate Pharmacological Action.
*To Determine Side EffectsConducted on 600 Adult Patients
Purpose: To Start Efficacy Studies and
selecting Dose for Phase III
*To Evaluate Effectiveness for Proposed
Indication
*Short Term Side Effects and RisksOn 2500 Patients with 40 weeks follow up
Purpose: To Ensure Efficacy.
*To Evaluate Benefit to Risk Ratio.
*To Collect additional data for Establishing
Physician Labeling.
![Page 13: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/13.jpg)
13
eCTD via Electronic Submission Gateway:
-FDA Form 356h
-FDA 3397: User Fee Cover Sheet
Payment of User Fees by PDUFA IV
$1,841,500 via Wire Transfer to U.S. bank in
St. Louis.
Submission of12 copies of Final Printed
Label with NDA.
![Page 14: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/14.jpg)
Establishment:
-Risk Evaluation and Mitigation Strategies
-RiskMAPs
REMS Includes:
Medication Guide
Package Insert
Communication Plan for HCP’s.
14
![Page 15: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/15.jpg)
Post Marketing Plans:
Clinical Studies for Secondary Indications.
Pediatric Population
Launching Dosage Strengths
Free Patients Counseling
Promotional Campaign
Committed for Safety Reporting
15
![Page 16: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/16.jpg)
Thank You for Your
Attention
16
![Page 17: 6201 gausroid presentation gitanjali avhad & umesh soni](https://reader034.vdocument.in/reader034/viewer/2022052400/5598d3cf1a28ab8c0d8b46db/html5/thumbnails/17.jpg)
17